CN102887838A - Preparation method of guanfacine hydrochloride - Google Patents
Preparation method of guanfacine hydrochloride Download PDFInfo
- Publication number
- CN102887838A CN102887838A CN2012104201763A CN201210420176A CN102887838A CN 102887838 A CN102887838 A CN 102887838A CN 2012104201763 A CN2012104201763 A CN 2012104201763A CN 201210420176 A CN201210420176 A CN 201210420176A CN 102887838 A CN102887838 A CN 102887838A
- Authority
- CN
- China
- Prior art keywords
- preparation
- solution
- guanfacine
- fenac
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域 technical field
本发明涉及制药领域关于药物制备技术,特别是涉及一种盐酸胍法辛的制备方法。 The invention relates to the pharmaceutical preparation technology in the field of pharmacy, in particular to a preparation method of guanfacine hydrochloride.
背景技术 Background technique
盐酸胍法辛属于抗高血压药物,用于治疗中度至重度高血压。化学名称为N-脒基-2-(2,6-二氯苯基)乙酰胺单盐酸盐,其分子式为:C9H9Cl2 N3O·HCl,分子量为282.55,结构式为: Guanfacine hydrochloride is an antihypertensive drug used to treat moderate to severe hypertension. The chemical name is N-amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride, its molecular formula is: C 9 H 9 Cl 2 N 3 O·HCl, its molecular weight is 282.55, and its structural formula is:
盐酸胍法辛为白色至类白色结晶粉末,难溶于水和乙醇,在甲醇中有相对较高的溶解度(>30mg/mg)。 Guanfacine hydrochloride is a white to off-white crystalline powder, insoluble in water and ethanol, and has a relatively high solubility in methanol (>30mg/mg).
盐酸胍法辛是选择性α2-肾上腺素受体增效剂,最早用于治疗中度至重度高血压,以口服给药的片剂给药,在美国的商品名为Tenex,规格为1mg或2mg。 Guanfacine hydrochloride is a selective α 2 -adrenergic receptor potentiator, which was first used in the treatment of moderate to severe hypertension. , the specification is 1mg or 2mg.
由于盐酸胍法辛该药物具有很强的中枢作用,且该药物血浆蛋白结合率高,普通剂型释放速率过快使得血药浓度峰值偏高,诱发其副作用,如倦睡、头晕、入睡困难、恶心、呕吐、健忘等。 Since guanfacine hydrochloride has a strong central action, and the drug has a high plasma protein binding rate, the release rate of the common dosage form is too fast, resulting in a high peak blood concentration, which induces side effects, such as drowsiness, dizziness, difficulty falling asleep, Nausea, vomiting, forgetfulness, etc.
发明内容 Contents of the invention
本发明要解决的技术问题是针对盐酸胍法辛现有制备方法存在的不足之处,提供一种操作更加简便、生产成本较低、工艺操作步骤简单、收率及纯度较高的盐酸胍法辛的制备方法。 The technical problem to be solved in the present invention is to provide a guanfacine hydrochloride method with simpler operation, lower production cost, simple process steps, higher yield and higher purity in view of the deficiencies in the existing preparation methods of guanfacine hydrochloride. Xin's preparation method.
为了解决上述问题,本发明采用的技术方案是: In order to solve the above problems, the technical solution adopted in the present invention is:
本发明提供一种盐酸胍法辛的制备方法,所述制备方法包括以下步骤: The present invention provides a kind of preparation method of guanfacine hydrochloride, described preparation method comprises the following steps:
a、2,6-二氯苯乙酸甲酯的制备: a, the preparation of 2,6-dichlorophenylacetic acid methyl ester:
以2,6-二氯苯乙酸和甲醇为原料,以浓硫酸(采用的浓硫酸的质量百分浓度为98%)为催化剂,首先将原料甲醇加入反应容器中,然后加入原料2,6-二氯苯乙酸,滴加催化剂浓硫酸,进行加热回流,2,6-二氯苯乙酸和甲醇在80~90 ℃下进行酯化反应,经TLC测定至原料点消失,则为酯化反应终点;酯化反应结束后除去过量的甲醇,将所得反应液倒入冰水中混合得到溶液,然后采用乙酸乙酯对得到的溶液进行萃取,萃取后合并有机相,采用饱和碳酸氢钠对所得有机相进行洗涤、无水硫酸钠进行干燥、过滤,最后蒸除乙酸乙酯,得到无色透明液体即为2,6-二氯苯乙酸甲酯;
Using 2,6-dichlorophenylacetic acid and methanol as raw materials, using concentrated sulfuric acid (concentrated sulfuric acid with a mass percentage concentration of 98%) as a catalyst, first add raw material methanol into the reaction vessel, and then add
所述甲醇加入的体积量为2,6-二氯苯乙酸质量的4~6倍;所述浓硫酸的加入量为2,6-二氯苯乙酸摩尔量的1~3倍; The volume of methanol added is 4 to 6 times the mass of 2,6-dichlorophenylacetic acid; the added amount of concentrated sulfuric acid is 1 to 3 times the molar weight of 2,6-dichlorophenylacetic acid;
b、游离胍乙醇溶液的制备: B, the preparation of free guanidine ethanol solution:
首先将无水乙醇加入到工业级乙醇钠中充分溶解,得到工业级乙醇钠乙醇溶液,然后在室温条件下加入盐酸胍,盐酸胍加入的质量为工业级乙醇钠质量的1~2倍,加入后进行充分搅拌,反应16~24 h,反应结束后进行过滤,得到游离胍乙醇溶液; First, absolute ethanol is added to technical grade sodium ethoxide to fully dissolve to obtain technical grade sodium ethoxide ethanol solution, then guanidine hydrochloride is added at room temperature, the quality of guanidine hydrochloride added is 1 to 2 times the quality of technical grade sodium ethoxide, and Afterwards, fully stir, react for 16-24 h, and filter after the reaction to obtain free guanidine ethanol solution;
c、胍法辛的制备: c, the preparation of guanfacine:
将步骤a制备得到的2,6-二氯苯乙酸甲酯溶于体积为2,6-二氯苯乙酸甲酯质量2~4倍的无水乙醇中,得到2,6-二氯苯乙酸甲酯溶液;然后滴加2~3倍于2,6-二氯苯乙酸甲酯溶液体积量的步骤b制备的游离胍乙醇溶液进行搅拌,在室温条件下进行反应,经TLC测定,当2,6-二氯苯乙酸甲酯的点消失时,则反应到终点,反应结束后旋干乙醇,将所得反应物采用二氯甲烷进行洗涤、抽滤,抽滤后进行真空干燥,干燥后得到白色固体即为胍法辛; Dissolving the 2,6-dichlorophenylacetic acid methyl ester prepared in step a in absolute ethanol whose volume is 2 to 4 times the mass of 2,6-dichlorophenylacetic acid methyl ester to obtain 2,6-dichlorophenylacetic acid Methyl ester solution; then dropwise add 2 to 3 times the free guanidine ethanol solution prepared in step b of the volume of 2,6-dichlorophenylacetic acid methyl ester solution to stir, and react at room temperature, as measured by TLC, when 2 , when the point of methyl 6-dichlorophenylacetate disappears, the reaction reaches the end point. After the reaction, the ethanol is spin-dried, and the obtained reactant is washed with dichloromethane, suction filtered, vacuum-dried after suction filtration, and obtained after drying The white solid is guanfacine;
d、盐酸胍法辛的制备: d, the preparation of guanfacine hydrochloride:
将步骤c制备的胍法辛加入1~2倍体积量的无水乙醇中进行搅拌悬浮,然后滴加1~2倍体积量的氯化氢乙醇溶液进行搅拌,在20~40℃条件下反应6~12h,反应后得到反应产物,对其所得反应产物进行过滤,过滤后进行真空干燥,干燥后得到白色固体为盐酸胍法辛产品。 Add guanfacine prepared in step c to 1 to 2 times the volume of absolute ethanol for stirring and suspension, then dropwise add 1 to 2 times the volume of hydrogen chloride ethanol solution for stirring, and react at 20 to 40°C for 6 to After 12 hours of reaction, a reaction product was obtained, and the obtained reaction product was filtered, and then vacuum-dried to obtain a white solid after drying, which was the product of guanfacine hydrochloride.
根据上述的盐酸胍法辛的制备方法,步骤a中所述将所得反应液倒入冰水中混合得到溶液,该过程中冰水与所得反应液二者之间加入的体积比为3~5:1。 According to the above-mentioned preparation method of guanfacine hydrochloride, the reaction solution obtained in step a is poured into ice water and mixed to obtain a solution. During this process, the volume ratio between the ice water and the reaction solution obtained is 3 to 5: 1.
根据上述的盐酸胍法辛的制备方法,步骤a中所述然后采用乙酸乙酯对得到的溶液进行萃取,萃取过程中乙酸乙酯与得到的溶液二者之间加入的体积比为3~5:1。 According to the above-mentioned preparation method of guanfacine hydrochloride, as described in step a, ethyl acetate is then used to extract the obtained solution, and the volume ratio between ethyl acetate and the obtained solution is 3 to 5 during the extraction process. :1.
根据上述的盐酸胍法辛的制备方法,步骤b中所述首先将无水乙醇加入到工业级乙醇钠中充分溶解,该过程中无水乙醇加入的体积为工业级乙醇钠质量的4~6倍。 According to the above-mentioned preparation method of guanfacine hydrochloride, as described in step b, at first dehydrated alcohol is added into technical grade sodium ethoxide and fully dissolved, and the volume of dehydrated alcohol added in this process is 4~6 of the quality of technical grade sodium ethoxide. times.
根据上述的盐酸胍法辛的制备方法,步骤c中所述抽滤后进行真空干燥,其真空干燥的条件是真空度为0.06~0.09 mPa,温度为50~70℃,干燥时间为12~16 h。 According to the above-mentioned preparation method of guanfacine hydrochloride, vacuum drying is carried out after the suction filtration described in step c, and the conditions for vacuum drying are that the vacuum degree is 0.06-0.09 mPa, the temperature is 50-70 ° C, and the drying time is 12-16 mPa. h.
根据上述的盐酸胍法辛的制备方法,步骤d中所述过滤后进行真空干燥,其真空干燥的条件是真空度为0.06~0.09 mPa,温度为50~70℃,干燥时间为12~16 h。 According to the above-mentioned preparation method of guanfacine hydrochloride, vacuum drying is carried out after filtering as described in step d, and the conditions of vacuum drying are that the vacuum degree is 0.06-0.09 mPa, the temperature is 50-70°C, and the drying time is 12-16 h .
本发明的积极有益效果:Positive beneficial effect of the present invention:
1、本发明技术方案选择2,6-二氯苯乙酸为起始原料,在浓硫酸催化下在甲醇中甲酯化得到2,6-二氯苯乙酸甲酯,再在游离胍乙醇溶液胍解得到胍法辛,胍法辛在乙醇氯化氢溶液中成盐得到盐酸胍法辛。 1. The technical scheme of the present invention selects 2,6-dichlorophenylacetic acid as the starting raw material, methyl esterifies in methanol under the catalysis of concentrated sulfuric acid to obtain 2,6-dichlorophenylacetic acid methyl ester, and then guanidine in free guanidine ethanol solution Decomposition obtains guanfacine, and guanfacine is salified in ethanol hydrogen chloride solution to obtain guanfacine hydrochloride.
2、本发明技术方案选用了成本低廉来源广泛的工业级乙醇钠乙醇溶液改进了游离胍的制备工艺,避免使用价格较贵的异丙醇钠和异丙醇,乙醇做溶剂更加容易回收,并可直接回收套用,这使得制备成本大大降低,操作更加简便。本发明技术方案采用的工艺操作步骤简单,工艺稳定。 2, the technical scheme of the present invention has selected the industrial grade sodium ethylate ethanol solution with low cost and wide sources to improve the preparation process of free guanidine, avoiding the use of more expensive sodium isopropoxide and isopropanol, and ethanol is easier to recycle as a solvent, and It can be recycled directly, which greatly reduces the preparation cost and makes the operation easier. The technological operation steps adopted by the technical solution of the present invention are simple and the technological process is stable.
3、采用本发明技术方案制备盐酸胍法辛,其收率及纯度得到了提高。本发明技术方案与现有盐酸胍法辛制备方法相比,本发明收率提高了50%(文献Bream JB et al. Arzneim-Forsch, 1975, 25:1477报道摩尔总收率为27.2%,本发明总摩尔收率为77.5%);本发明所得产品盐酸胍法辛的液相纯度为100%,各项技术指标符合USP34标准。 3. Adopt the technical scheme of the present invention to prepare guanfacine hydrochloride, and its yield and purity have been improved. Technical scheme of the present invention compares with existing guanfacine hydrochloride preparation method, and the yield of the present invention has improved 50% (document Bream JB et al. Arzneim-Forsch, 1975, 25:1477 report molar total yield is 27.2%, this The total molar yield of the invention is 77.5%); the liquid phase purity of the product guanfacine hydrochloride obtained in the present invention is 100%, and each technical index meets the USP34 standard.
4、利用本发明技术方案可制备得到产品盐酸胍法辛,由附图1、2和3进行证明,由附图1-3充分说明了,利用本发明技术方案制备所得产品为盐酸胍法辛。
4. The product guanfacine hydrochloride can be prepared by utilizing the technical solution of the present invention, which is proved by accompanying
附图说明:Description of drawings:
图1 本发明所得产品盐酸胍法辛的红外吸收光谱图; Fig. 1 The infrared absorption spectrogram of product Guanfacine hydrochloride obtained from the present invention;
图2 本发明所得产品盐酸胍法辛的氢谱图; Fig. 2 The hydrogen spectrogram of product Guanfacine hydrochloride obtained from the present invention;
图3 本发明所得产品盐酸胍法辛的质谱图。 Fig. 3 is the mass spectrogram of product guanfacine hydrochloride obtained in the present invention.
具体实施方式:Detailed ways:
以下结合实施例进一步阐述本发明,但并不限制本发明的内容。 The present invention is further set forth below in conjunction with embodiment, but content of the present invention is not limited.
实施例1:本发明盐酸胍法辛的制备方法,所述制备方法的详细步骤如下: Embodiment 1: the preparation method of guanfacine hydrochloride of the present invention, the detailed steps of described preparation method are as follows:
a、2,6-二氯苯乙酸甲酯的制备: a, the preparation of 2,6-dichlorophenylacetic acid methyl ester:
以2,6-二氯苯乙酸和甲醇为原料,以浓硫酸(浓硫酸的质量百分浓度为98%)为催化剂,甲醇加入的体积量为2,6-二氯苯乙酸质量的5倍,浓硫酸加入的质量为2,6-二氯苯乙酸质量的1倍; Using 2,6-dichlorophenylacetic acid and methanol as raw materials, using concentrated sulfuric acid (98% concentration of concentrated sulfuric acid by mass) as a catalyst, the volume of methanol added is 5 times the mass of 2,6-dichlorophenylacetic acid , the quality of concentrated sulfuric acid added is 1 times of the quality of 2,6-dichlorophenylacetic acid;
首先将原料甲醇加入反应容器中,然后加入原料2,6-二氯苯乙酸,滴加催化剂浓硫酸,进行加热回流,2,6-二氯苯乙酸和甲醇在85℃下进行酯化反应,经TLC测定至原料点消失,则为酯化反应终点;酯化反应结束后除去过量的甲醇,将所得反应液倒入冰水中混合得到溶液(冰水与所得反应液二者之间加入的体积比为4:1),然后采用乙酸乙酯对得到的溶液进行萃取(乙酸乙酯与得到的溶液二者之间加入的体积比为4:1),萃取后合并有机相,采用饱和碳酸氢钠对所得有机相进行洗涤,无水硫酸钠进行干燥、过滤,最后蒸除乙酸乙酯,得到无色透明液体即为2,6-二氯苯乙酸甲酯;
First, the raw material methanol is added to the reaction vessel, then the
b、游离胍乙醇溶液的制备: B, the preparation of free guanidine ethanol solution:
首先将无水乙醇加入到工业级乙醇钠中充分溶解(无水乙醇加入的体积为工业级乙醇钠质量的5倍),得到工业级乙醇钠乙醇溶液,然后在室温条件下加入盐酸胍,盐酸胍加入的质量为工业级乙醇钠质量的2倍,加入后进行充分搅拌,反应20h,反应结束后进行过滤,得到游离胍乙醇溶液; First add absolute ethanol to industrial grade sodium ethoxide to fully dissolve (the volume of absolute ethanol added is 5 times the mass of industrial grade sodium ethoxide) to obtain industrial grade sodium ethoxide ethanol solution, then add guanidine hydrochloride and hydrochloric acid at room temperature The quality of guanidine added is 2 times of the quality of industrial-grade sodium ethylate, fully stirred after adding, reacted for 20h, and filtered after the reaction to obtain free guanidine ethanol solution;
c、胍法辛的制备: c, the preparation of guanfacine:
将步骤a制备得到的2,6-二氯苯乙酸甲酯溶于体积为2,6-二氯苯乙酸甲酯质量3倍的无水乙醇中,得到2,6-二氯苯乙酸甲酯溶液;然后滴加3倍于2,6-二氯苯乙酸甲酯溶液体积量的步骤b制备的游离胍乙醇溶液进行搅拌,在室温条件下进行反应,经TLC测定,当2,6-二氯苯乙酸甲酯的点消失时,则反应到终点,反应结束后旋干乙醇,将所得反应物采用二氯甲烷进行洗涤、抽滤,抽滤后进行真空干燥(真空度为0.08mPa,温度为60℃,干燥时间为14 h),干燥后得到白色固体即为胍法辛; Dissolve the 2,6-dichlorophenylacetic acid methyl ester prepared in step a in absolute ethanol whose volume is 3 times the mass of 2,6-dichlorophenylacetic acid methyl ester to obtain 2,6-dichlorophenylacetic acid methyl ester solution; then dropwise add 3 times the free guanidine ethanol solution prepared in step b of the volume of 2,6-dichlorophenylacetic acid methyl ester solution to stir, and react at room temperature, as determined by TLC, when 2,6-dichlorophenylacetic acid When the point of methyl chlorophenylacetate disappears, the reaction reaches the end point. After the reaction, the ethanol is spin-dried, and the gained reactant is washed with dichloromethane, suction filtered, and vacuum-dried after the suction filtration (vacuum degree is 0.08mPa, temperature at 60°C, and the drying time was 14 h), the white solid obtained after drying was guanfacine;
d、盐酸胍法辛的制备: d, the preparation of guanfacine hydrochloride:
将步骤c制备的胍法辛加入2倍体积量的无水乙醇中进行搅拌悬浮,然后滴加2倍体积量的氯化氢乙醇溶液进行搅拌,在30℃条件下反应9h,反应后得到反应产物,对其所得反应产物进行过滤,过滤后进行真空干燥(真空度为0.08mPa,温度为60℃,干燥时间为14 h),干燥后得到白色固体为盐酸胍法辛产品。 Add guanfacine prepared in step c to 2 times the volume of absolute ethanol for stirring and suspension, then dropwise add 2 times the volume of hydrogen chloride ethanol solution for stirring, react at 30°C for 9 hours, and obtain the reaction product after the reaction, The resulting reaction product was filtered, and then vacuum-dried (vacuum degree of 0.08 mPa, temperature of 60°C, drying time of 14 h), and a white solid was obtained after drying, which was the product of guanfacine hydrochloride.
实施例2:与实施例1基本相同,不同之处在于:
Embodiment 2: basically the same as
步骤a中:甲醇加入的体积量为2,6-二氯苯乙酸质量的4倍,浓硫酸加入的质量为2,6-二氯苯乙酸质量的0.5倍; In step a: the volume of methanol added is 4 times the mass of 2,6-dichlorophenylacetic acid, and the mass of concentrated sulfuric acid added is 0.5 times the mass of 2,6-dichlorophenylacetic acid;
2,6-二氯苯乙酸和甲醇在80℃下进行酯化反应;将所得反应液倒入冰水中混合得到溶液(冰水与所得反应液二者之间加入的体积比为3:1),然后采用乙酸乙酯对得到的溶液进行萃取(乙酸乙酯与得到的溶液二者之间加入的体积比为3:1); 2,6-dichlorophenylacetic acid and methanol are subjected to esterification reaction at 80°C; the resulting reaction solution is poured into ice water and mixed to obtain a solution (the volume ratio between ice water and the obtained reaction solution is 3:1) , and then use ethyl acetate to extract the obtained solution (the volume ratio between ethyl acetate and the obtained solution is 3:1);
步骤b中:首先将无水乙醇加入到工业级乙醇钠中充分溶解(无水乙醇加入的体积为工业级乙醇钠质量的6倍),得到工业级乙醇钠乙醇溶液;盐酸胍加入的质量为工业级乙醇钠质量的1.5倍,加入后进行充分搅拌,反应24h; In step b: at first dehydrated alcohol is added in technical grade sodium ethylate and fully dissolved (the volume that dehydrated alcohol adds is 6 times of technical grade sodium ethylate quality), obtains technical grade sodium ethylate ethanolic solution; The quality that guanidine hydrochloride adds is 1.5 times the mass of industrial grade sodium ethoxide, fully stirred after adding, and reacted for 24 hours;
步骤c中:将步骤a制备得到的2,6-二氯苯乙酸甲酯溶于体积为2,6-二氯苯乙酸甲酯质量4倍的无水乙醇中;然后滴加2.5倍于2,6-二氯苯乙酸甲酯溶液体积量的步骤b制备的游离胍乙醇溶液进行搅拌;抽滤后进行真空干燥(真空度为0.09mPa,温度为50℃,干燥时间为12 h); In step c: dissolve the 2,6-dichlorophenylacetic acid methyl ester prepared in step a in dehydrated alcohol whose volume is 4 times the mass of 2,6-dichlorophenylacetic acid methyl ester; then dropwise add 2.5 times to 2 , Stir the free guanidine ethanol solution prepared in step b of the volume of 6-dichlorophenylacetic acid methyl ester solution; carry out vacuum drying after suction filtration (vacuum degree is 0.09mPa, temperature is 50°C, and drying time is 12 h);
步骤d中:将步骤c制备的胍法辛加入1.5倍体积量的无水乙醇中进行搅拌悬浮,然后滴加1.5倍体积量的氯化氢乙醇溶液进行搅拌,在20℃条件下反应12h,反应后得到反应产物,对其所得反应产物进行过滤,过滤后进行真空干燥(真空度为0.09mPa,温度为50℃,干燥时间为12 h)。 In step d: add the guanfacine prepared in step c to 1.5 times the volume of absolute ethanol for stirring and suspension, then dropwise add 1.5 times the volume of hydrogen chloride ethanol solution for stirring, and react at 20°C for 12h, after the reaction The reaction product was obtained, and the obtained reaction product was filtered, and then vacuum-dried (vacuum degree of 0.09mPa, temperature of 50°C, and drying time of 12 h).
实施例3:与实施例1基本相同,不同之处在于:
Embodiment 3: basically the same as
步骤a中:甲醇加入的体积量为2,6-二氯苯乙酸质量的6倍,浓硫酸加入的质量为2,6-二氯苯乙酸质量的1.5倍; In step a: the volume of methanol added is 6 times the mass of 2,6-dichlorophenylacetic acid, and the mass of concentrated sulfuric acid added is 1.5 times the mass of 2,6-dichlorophenylacetic acid;
2,6-二氯苯乙酸和甲醇在90℃下进行酯化反应;将所得反应液倒入冰水中混合得到溶液(冰水与所得反应液二者之间加入的体积比为5:1),然后采用乙酸乙酯对得到的溶液进行萃取(乙酸乙酯与得到的溶液二者之间加入的体积比为5:1); 2,6-dichlorophenylacetic acid and methanol are subjected to esterification reaction at 90°C; the resulting reaction solution is poured into ice water and mixed to obtain a solution (the volume ratio between ice water and the resulting reaction solution is 5:1) , and then use ethyl acetate to extract the obtained solution (the volume ratio between ethyl acetate and the obtained solution is 5:1);
步骤b中:首先将无水乙醇加入到工业级乙醇钠中充分溶解(无水乙醇加入的体积为工业级乙醇钠质量的4倍),得到工业级乙醇钠乙醇溶液;盐酸胍加入的质量为工业级乙醇钠质量的1倍,加入后进行充分搅拌,反应18h; In step b: at first dehydrated alcohol is joined in technical grade sodium ethylate and fully dissolved (the volume that dehydrated alcohol adds is 4 times of technical grade sodium ethylate quality), obtains technical grade sodium ethylate ethanolic solution; The quality that guanidine hydrochloride adds is 1 times the mass of industrial grade sodium ethoxide, fully stirred after adding, and reacted for 18 hours;
步骤c中:将步骤a制备得到的2,6-二氯苯乙酸甲酯溶于体积为2,6-二氯苯乙酸甲酯质量2倍的无水乙醇中;然后滴加2倍于2,6-二氯苯乙酸甲酯溶液体积量的步骤b制备的游离胍乙醇溶液进行搅拌;抽滤后进行真空干燥(真空度为0.06mPa,温度为70℃,干燥时间为12 h); In step c: dissolve the 2,6-dichlorophenylacetic acid methyl ester prepared in step a in dehydrated alcohol whose volume is 2 times the mass of 2,6-dichlorophenylacetic acid methyl ester; then dropwise add 2 times to 2 , Stir the free guanidine ethanol solution prepared in step b of the volume of 6-dichlorophenylacetic acid methyl ester solution; carry out vacuum drying after suction filtration (vacuum degree is 0.06mPa, temperature is 70°C, and drying time is 12 h);
步骤d中:将步骤c制备的胍法辛加入1倍体积量的无水乙醇中进行搅拌悬浮,然后滴加1倍体积量的氯化氢乙醇溶液进行搅拌,在40℃条件下反应6h,反应后得到反应产物,对其所得反应产物进行过滤,过滤后进行真空干燥(真空度为0.06mPa,温度为70℃,干燥时间为12 h)。 In step d: Add guanfacine prepared in step c to 1 volume of absolute ethanol for stirring and suspension, then dropwise add 1 volume of hydrogen chloride ethanol solution for stirring, and react at 40°C for 6 hours, after the reaction The reaction product was obtained, and the obtained reaction product was filtered, and then vacuum-dried (vacuum degree of 0.06mPa, temperature of 70°C, and drying time of 12 h).
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104201763A CN102887838A (en) | 2012-10-29 | 2012-10-29 | Preparation method of guanfacine hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104201763A CN102887838A (en) | 2012-10-29 | 2012-10-29 | Preparation method of guanfacine hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102887838A true CN102887838A (en) | 2013-01-23 |
Family
ID=47531539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104201763A Pending CN102887838A (en) | 2012-10-29 | 2012-10-29 | Preparation method of guanfacine hydrochloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102887838A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115028554A (en) * | 2022-08-10 | 2022-09-09 | 广东科泰鼎润药业科技有限公司 | Guanfacine hydrochloride and preparation method thereof |
| CN115286539A (en) * | 2022-08-09 | 2022-11-04 | 梯尔希(南京)药物研发有限公司 | Preparation method of guanfacine metabolite |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634508A (en) * | 1969-02-20 | 1972-01-11 | A Wander Sa Dr | Phenylacetylguanidines |
| US4380550A (en) * | 1981-06-01 | 1983-04-19 | Sandoz Ltd. | Guanfacine in treating opiate addiction |
| EP0164320A1 (en) * | 1984-03-14 | 1985-12-11 | Astra Läkemedel Aktiebolag | Pharmaceutical preparations for spinal analgesia containing guanfacine, and method for their preparation |
| US20090076019A1 (en) * | 2006-10-13 | 2009-03-19 | Mount Sinai Hospital | Methods for treating neurological disorders or damage |
| CN102267926A (en) * | 2011-08-05 | 2011-12-07 | 北京德众万全药物技术开发有限公司 | Crystal form A of guanfacine hydrochloride and preparation method thereof |
| CN102579381A (en) * | 2012-03-30 | 2012-07-18 | 河南中帅医药科技发展有限公司 | Guanidine hydrochloride sustained release preparation and preparation method thereof |
-
2012
- 2012-10-29 CN CN2012104201763A patent/CN102887838A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634508A (en) * | 1969-02-20 | 1972-01-11 | A Wander Sa Dr | Phenylacetylguanidines |
| US4380550A (en) * | 1981-06-01 | 1983-04-19 | Sandoz Ltd. | Guanfacine in treating opiate addiction |
| EP0164320A1 (en) * | 1984-03-14 | 1985-12-11 | Astra Läkemedel Aktiebolag | Pharmaceutical preparations for spinal analgesia containing guanfacine, and method for their preparation |
| US20090076019A1 (en) * | 2006-10-13 | 2009-03-19 | Mount Sinai Hospital | Methods for treating neurological disorders or damage |
| CN102267926A (en) * | 2011-08-05 | 2011-12-07 | 北京德众万全药物技术开发有限公司 | Crystal form A of guanfacine hydrochloride and preparation method thereof |
| CN102579381A (en) * | 2012-03-30 | 2012-07-18 | 河南中帅医药科技发展有限公司 | Guanidine hydrochloride sustained release preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| BREAM ET AL: "Substituted Phenylacetylguanidines:a new Class of Antihypertensive Agents", 《ARZNEIM-FORSCH DRUG RES》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115286539A (en) * | 2022-08-09 | 2022-11-04 | 梯尔希(南京)药物研发有限公司 | Preparation method of guanfacine metabolite |
| CN115286539B (en) * | 2022-08-09 | 2023-08-18 | 梯尔希(南京)药物研发有限公司 | Preparation method of guanfacine metabolite |
| CN115028554A (en) * | 2022-08-10 | 2022-09-09 | 广东科泰鼎润药业科技有限公司 | Guanfacine hydrochloride and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5426693B2 (en) | Agomelatine hydrogen halide complex and method for producing the same | |
| CN102887838A (en) | Preparation method of guanfacine hydrochloride | |
| CN102976948B (en) | Method for preparing nitisinone | |
| CN103804234B (en) | The synthetic method of Alpha-Methyl-(3,4-Dimethoxyphenyl)-alpha-amino group propionitrile | |
| CN101085771B (en) | Method for preparing rizatriptan benzoate | |
| CN103183602A (en) | Method for crystallizing 2,2-dipropylmalonic acid | |
| CN102241663B (en) | Preparation method of strontium ranelate octohydrate | |
| CN101003476B (en) | A kind of preparation technology of divalproex sodium | |
| CN102391170B (en) | A kind of preparation method of N, N-diallyl-5-methoxytryptamine hydrochlorides | |
| CN102010361B (en) | Method for preparing amlodipine intermediate | |
| CN101747343B (en) | A kind of preparation method of sulbactam pivoxil | |
| CN101492412B (en) | Synthesis of carprofen | |
| CN100390172C (en) | A kind of crystal form of dolasetron mesylate and preparation method thereof | |
| CN104844512B (en) | A kind of preparation method of green card color woods hydrochloride semi-hydrate crystal formation | |
| CN117069653B (en) | Milrinone-gallic acid eutectic | |
| CN104098552A (en) | Preparation method of vilazodone | |
| CN117050060A (en) | Preparation method of ilaprazole crystal form F | |
| CN110835319B (en) | A kind of synthetic method of benazepril intermediate and benazepril hydrochloride | |
| CN103880746A (en) | Chemical synthetic method for (s)-3-(Boc-amino)azacycloheptane | |
| CN102030688B (en) | Method for preparing monosodium sulfosuccinate | |
| CN107298655A (en) | 7,8 dimethoxy 2,3,4,5 tetrahydrochysene 1H benzos [c] azatropylidene hydrochloride and preparation method thereof | |
| CN106542961A (en) | A kind of synthetic method of racecadotril intermediate | |
| CN102285914B (en) | Synthesis method of 2-(1-methyl-6-carboxy-1,6-dihydropyridine)-acetic acid | |
| CN102174116B (en) | 1-amantadine hydrochloride carboxylic acid cellulose ester and method for preparing same | |
| CN105254670A (en) | Preparation method of (R)-9-[2-(phosphonomethoxy) propyl] adenine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 18 building, No. 450001, block A, No. 7, holly, Zhengzhou hi tech Industrial Development Zone, Henan, China Applicant after: ZHONGSHUAI PHARMACEUTICAL SCI & TECH INCORPORATED CO., LTD. Address before: 18 building, No. 450001, block A, No. 7, holly, Zhengzhou hi tech Industrial Development Zone, Henan, China Applicant before: Henan Zhongshuai Pharmaceutical Science Development Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ZHONGSHUAI PHARMACEUTICAL SCI+TECH DEVELOPMENT CO., LTD. TO: ZHONGSHUAI PHARMACEUTICAL SCIENCE AND TECHNOLOGY INCORPORATED CO., LTD. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130123 |